| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2027 ( Subtotal = -$1 ) |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258981 | The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML | 000 | 5 | NIH | 10/20/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R00AR084575 | Investigating the Role of Cancer-Associated Fibroblasts in Immunodetection of Mycosis Fungoides | 000 | 3 | NIH | 10/16/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01DK134652 | Role of trefoil factor family proteins in beta cell function. | 000 | 4 | NIH | 10/13/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R03DE034794 | Protein Phosphoribosylation: Characterization of a novel protein modification | 000 | 2 | NIH | 11/6/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | U24DK104162 | Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN). | 000 | 13 | NIH | 10/30/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | U24DK104162 | Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN). | 000 | 13 | NIH | 10/30/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA258778 | Targeting tumor-associated macrophages for triple-negative breast cancer treatment | 000 | 5 | NIH | 11/11/2026 | $0 |
| | 2027 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA279840 | Okazaki fragment maturation: mutagenesis and cell survival | 000 | 4 | NIH | 11/4/2026 | $0 |
| | 2027 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA265095 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | 000 | 5 | NIH | 10/20/2026 | $0 |
| | 2027 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA205247 | Targeting MicroRNAs to Eradicate Leukemia Stem Cells | 000 | 9 | NIH | 10/20/2026 | $0 |
| | 2027 | 2025 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA262754 | The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma | 000 | 5 | NIH | 10/14/2026 | $0 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R21CA293969 | Modulating Intratumoral Immune Composition to Enhance Immunotherapy | 000 | 1 | NIH | 10/23/2026 | $0 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | K08CA252157 | Multi-antigen-specific CAR T cells to treat acute myeloid leukemia | 000 | 5 | NIH | 10/21/2026 | $0 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL124112 | Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | 000 | 11 | NIH | 11/9/2026 | $0 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01DK125856 | Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes | 000 | 4 | NIH | 10/26/2026 | -$1 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R21AR084116 | Concurrent eradication of pathogenic plasma cells and their precursors in systemic lupus erythematosus | 000 | 1 | NIH | 10/20/2026 | $0 |
| | 2027 | 2024 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R21AR084116 | Concurrent eradication of pathogenic plasma cells and their precursors in systemic lupus erythematosus | 000 | 1 | NIH | 10/20/2026 | $0 |
|
 | Issue Date FY: 2026 ( Subtotal = $88,372,540 ) (Continued on the next page) |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 001 | 4 | NIH | 4/1/2026 | $2,488 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32DK131943 | DIABETES PREVENTION / RISK / OMICS / METABOLISM / THERAPY (PROMT) INTERDISCIPLINARY TRAINING | 000 | 4 | NIH | 3/27/2026 | $89,205 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA298313 | Targeting Tumor-Associated Macrophages to Treat Lymphoma | 000 | 2 | NIH | 8/17/2026 | $718,036 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01ES034793 | Early Life Exposure to Endocrine Disrupting Chemicals: Epigenomic and Transcriptomic Networks and RAGE in Liver Disease | 000 | 3 | NIH | 4/10/2026 | $767,661 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266783 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation | 000 | 4 | NIH | 7/22/2026 | $646,643 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA271443 | Exosomal biomarkers for the early detection of hepatocellular carcinoma | 000 | 4 | NIH | 8/12/2026 | $727,899 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 003 | 5 | NIH | 4/6/2026 | $473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 002 | 5 | NIH | 4/2/2026 | -$473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266659 | The Novel Role and Mechanism of RBM33 in Leukemogenesis | 001 | 5 | NIH | 3/20/2026 | $473,946 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA266611 | Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | 000 | 5 | NIH | 9/9/2026 | $710,482 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01ES033514 | Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort | 000 | 5 | NIH | 4/28/2026 | $608,813 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA271497 | The role and therapeutic potential of IGF2BP2 in MLL-rearranged leukemia | 000 | 5 | NIH | 4/17/2026 | $574,091 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA262263 | Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos | 001 | 5 | NIH | 6/30/2026 | $690,799 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA272732 | Development of Microbial-Based Therapies to Suppress Macropinocytosis in Kras-Driven Cancers | 000 | 5 | NIH | 8/10/2026 | $402,600 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL173308 | Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | 001 | 2 | NIH | 3/20/2026 | $21,701 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01HL173308 | Novel mechanisms and therapeutics for Tyrosine Kinase Inhibitor-induced Cardiotoxicity | 000 | 2 | NIH | 2/23/2026 | $687,181 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | U01CA299594 | An exosome-based liquid biopsy assay for the non-invasive early detection of colorectal adenomas and cancers | 000 | 1 | NIH | 3/16/2026 | $738,675 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS132083 | Biological function and regulation of PRMT9 in synapse development | 000 | 3 | NIH | 1/23/2026 | $535,402 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS132083 | Biological function and regulation of PRMT9 in synapse development | 001 | 3 | NIH | 3/3/2026 | $59,488 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R33AG059206 | Geriatric Oncology Research Infrastructure to Improve Clinical Care | 001 | 9 | NIH | 7/21/2026 | $631,237 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA301510 | Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC) | 000 | 2 | NIH | 4/9/2026 | $772,905 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA299039 | The role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression | 000 | 2 | NIH | 3/31/2026 | $573,528 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01NS138604 | High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome | 000 | 2 | NIH | 2/25/2026 | $718,682 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA228308 | The role of bile acid metabolomics in graft-versus-host disease | 000 | 9 | NIH | 4/21/2026 | $585,843 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | UG1HL069278 | BMT CTN Core - City of Hope National Medical Center | 001 | 26 | NIH | 7/22/2026 | $264,000 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 001 | 10 | NIH | 4/16/2026 | $4,122 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | T32CA186895 | DNA Damage Response and Oncogenic Signaling | 000 | 10 | NIH | 2/24/2026 | $239,954 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 000 | 9 | NIH | 3/25/2026 | $226,709 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R25CA217270 | Preparing Oncology Advanced Practice Nurses as Generalists in Palliative Care | 001 | 9 | NIH | 5/4/2026 | $4,800 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R35CA210087 | Human natural killer cells: Advancing biology and clinical applications | 000 | 9 | NIH | 7/28/2026 | $886,438 |
| | 2026 | 2026 | BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE | 1500 DUARTE RD | DUARTE | CA | 91010 | LOS ANGELES | USA | R01CA292596 | Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia | 001 | 2 | NIH | 3/3/2026 | $738,698 |
|